EI
VERV

EAM Investors’s Verve Therapeutics VERV Stock Holding History

EAM Investors’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-23,572
Closed -$810K – 345
2022
Q3 		$810K Buy
+23,572
New +$752K 0.18% 237
2021
Q3 		– Sell
-28,413
Closed -$1.71M – 398
2021
Q2 		$1.71M Buy
+28,413
New +$1.18M 0.26% 168

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

EAM Investors's VERV Position: Q4 2022 in Review

EAM Investors sold out of Verve Therapeutics (VERV) in Q4 2022, closing a stake of 23,572 shares — an estimated $810K sold.

EAM Investors first reported a position in VERV in Q2 2021 and held it in 2 quarters. The position peaked at $1.71M in Q2 2021. 123 funds tracked by Wall St. Rank hold VERV as of Q4 2022.

  • EAM Investors reported no remaining Verve Therapeutics position as of Q4 2022 after selling out during the quarter.
  • EAM Investors sold 23,572 Verve Therapeutics shares in Q4 2022, an estimated $810K.
  • EAM Investors first reported a position in Verve Therapeutics in Q2 2021 and held it in 2 quarters.
  • EAM Investors's Verve Therapeutics position peaked at $1.71M in Q2 2021.
  • 123 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2022.

Based on EAM Investors's 13F filing for Q4 2022, filed 14 Feb 2023.